New HIV vaccine trial aims to spark rare antibodies that could fight the virus

NCT ID NCT06006546

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental HIV vaccine in 35 people living with HIV. The goal is to see if the vaccine can safely trigger the body to produce VRC01-class antibodies, which are known to neutralize many HIV strains. Participants will temporarily pause their antiretroviral therapy to see if the vaccine helps control the virus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atlanta- Ponce

    Atlanta, Georgia, 30303, United States

  • BIDMC

    Boston, Massachusetts, 02215, United States

  • Birmingham

    Birmingham, Alabama, 35294-2170, United States

  • Columbia P&S CRS Site#30329

    New York, New York, 10032, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109, United States

  • Seattle Vaccine and Prevention CRS (Site # 30331)

    Seattle, Washington, 98104, United States

  • The Hope Clinic of the Emory Vaccine Center CRS (Site #31440)

    Decatur, Georgia, 30030, United States

  • University of Pittsburg

    Pittsburgh, Pennsylvania, 15213, United States